The EDA rewrites its drug-pricing rulebook around costs, competition, and localization

The government has put drug pricing on a new rules-based footing, with the Egyptian Drug Authority (EDA) tying price reviews to a weighted mix of FX movements, inflation, and interest rates, under a new framework published in the Official Gazette on Wednesday, effective Thursday, 24 September. FX carries 60% of the formula, urban inflation 30%, and changes in the CBE’s overnight deposit rate the remaining 10%, with the calculation to be run every six months — or sooner in exceptional circumstances.

The problem the formula is designed to fix: “The lag between an economic shock and a price adjustment could stretch 6-9 months,” Ibn Sina Pharma IR head Mohamed Shawky tells EnterpriseAM. That gap created Egypt’s recurring drug shortages. Private companies covering 80-85% of domestic production cannot absorb sustained losses on regulated prices while input costs move with the market, he says. “These are for-profit companies — they cannot keep producing at a loss.”

The framework is “a strategic shift toward a more flexible pricing system based on an operational formula that reflects actual cost dimensions,” CI Capital tells us. It replaces the old approach that “relied only on exceptional reviews after successive FX shocks.” The investment bank’s research identifies five pillars: FX movements as the primary trigger; an expanded cost base that now includes packaging, manufacturing, electricity, fuel, and wages; tightened reference pricing for imports; a structural price advantage for local products; and transparency through pre-registration price estimates.

Why it matters: Egypt regulates drug prices to keep medicines affordable. The catch: prices are set in EGP, but more than 90% of raw materials are imported and priced in USD, EDA head Ali El Ghamrawy previously told us. When the EGP devalued sharply between 2022 and 2024, manufacturers’ costs spiked while selling prices stayed mostly fixed. The gap between production costs and approved prices became the sector’s defining pressure point.

The mechanics

How repricing works: A price increase can be considered when the formula produces a change of at least 10% and the underlying economic conditions persist for at least 45 days — but the increase is not automatic. The holder of the drug registration must request it. The same thresholds work in the opposite direction, with the EDA empowered to reduce prices when the formula points downward. Companies seeking a product-level review must wait at least six months from their latest pricing notice and submit supporting cost, reference-market, and economic-evaluation data.

The EDA keeps an override on the downside. The authority can independently revisit and reduce a medicine’s price using its cost structure, prices in reference markets, and comparable therapies, without waiting for the existing pricing notice to expire. Any lower price applies to batches produced or imported after the new pricing notice is issued. The decree applies to medicines priced or repriced after its issuance, rather than resetting every medicine already on pharmacy shelves.

When this reaches patients: “Products registered under the new system will not reach the market before 1Q 2027,” Federation of Egyptian Chambers of Commerce Pharma Division head Ali Ouf tells us. There are no price increases on currently traded medicines as long as the EGP stays below EGP 55 to the USD, he says. On the downside, if the USD falls 10% and stays there for 45 days, prices could drop 10-12%, and some drugs could decline 30-40% over the longer term as raw material costs ease and local production scales up, he notes.

Market entry and competition

New market entrants get a separate rulebook. Originator drugs submitted for first-time pricing are benchmarked against the lowest ex-factory price across a 15-country reference basket (Poland, Greece, Hungary, Spain, Finland, Norway, Romania, Belgium, Austria, the UK, Sweden, the UAE, Canada, Germany, and Denmark), with distributor and pharmacy margins added. The UAE’s inclusion gives the basket a regional dimension the previous 35-country list lacked. For medicines with a foreign ex-factory price between EGP 50k and EGP 500k, the framework can instead bring in value-based pricing. Drugs above EGP 500k are benchmarked to the lowest available foreign ex-factory price even outside the reference basket, with the first reassessment after nine months and a cap of three annual reviews.

A localization incentive built into the rules: Originator drugs that are fully localized, meaning their entire production chain moves to Egypt, are shielded from price cuts for five years from the date locally made packs hit the market. This aligns with the government’s broader push to localize strategic drugs — biosimilars, insulin, blood derivatives, and vaccines — where active-ingredient and excipient-localization investment is expected to exceed USD 500 mn. CI Capital notes that locally manufactured drugs are priced at 50-60% of the equivalent imported product, giving them “high pricing competitiveness.”

Competition is built into the price ladder. When no comparable product is trading locally yet, the first generic is priced at 70% of the originator, the second and third at 65%, the fourth and fifth at 60%, and the sixth onward at 50%. Biosimilars start higher, at 80% for the first entrant, 75% for the second and third, 70% for the fourth and fifth, and 60% from the sixth. Where competing products exist, the EDA uses the product’s cost structure and existing market prices. Once three generics are trading in sufficient volume, the originator’s price is cut by 20% or to the lowest reference-country price — whichever is lower.

Margins and distribution

Pharmacies and distributors get tiered margins: On locally made essential medicines, distributor / pharmacist margins are set at 8% / 22% for packs below EGP 500 and 5.8% / 20% above that threshold. Locally made non-essential drugs carry margins of 8.5% / 27% below EGP 500 and 6% / 25% above it, while fully imported finished medicines carry 7.4% / 19% and 4.8% / 15%, respectively. For high-priced medicines, the framework caps nominal margins by price band, topping out at EGP 4k for distributors and EGP 5k for pharmacists on products above EGP 200k.

The 8% distributor margin replaces the old “elgeneih elmaktu” — a flat per-strip fee that no longer covered costs, Shawky says. Distributors pushed for interest rates to be included in the formula because the working capital required to finance distribution to every pharmacy in Egypt makes them the most exposed link to rate swings. The cautionary tale is United Company for Trading for Distribution, which held 26-27% of the market, collapsing under accumulated debt and interest burdens when subsidized government financing went to manufacturers only, he notes.

Tracking and appeals

The national track-and-trace system goes live 16 October, CI Capital reports. The first phase covers about 1.3k imported and UPA-supplied medicines — less than 10% of total SKUs. The EDA mandates a GS1-compliant barcode standard to track drugs from manufacturing to patient. CI Capital expects full market coverage will take 6-12 months, since the system applies only to new batches produced after existing inventory sells through. The EDA is offering incentives for early adopters rather than penalties in the initial phase.

Tighter clocks for high-priced medicines and appeals: Pricing notices generally run for five years, but medicines priced above EGP 50k get two-year notices, on top of the more frequent reassessment rules for products above EGP 500k. Companies can challenge an EDA-set price within three months of being notified, with the regulator required to decide on the appeal within two months of submission.

Export pricing

Export pricing is now decoupled from domestic pricing: Gulf and other importing countries require visibility on a product’s domestic shelf price, Ouf says. Egypt’s historically low mandated prices were translating into low export prices, “making them lose profitability” abroad, he argues. A new pre-pricing simulation mechanism lets companies get an advance price estimate before completing registration, separating the export track from the domestic one, he adds. Shawky argues Egyptian manufacturers should compete on quality with French and American drugs rather than low-cost Indian and Chinese tiers. The sector targets USD 1.6 bn in exports by end-2026, USD 2 bn by 2027, and USD 3 bn by 2030, according to Ouf.

REMEMBER- This is the final version of an overhaul we first detailed earlier this month. The framework under discussion then centered on a 10% FX band, a smaller reference basket, and a simpler pricing advantage for locally made drugs. The published rulebook is more granular: the FX band has given way to a three-variable formula, with separate rules for originators, generics, biosimilars, high-cost therapies, and fully localized products.

IN CONTEXT- Pharma companies have spent much of this year pushing for a pricing system that responds faster to their actual cost base. Manufacturers have been caught between regulated EGP selling prices and imported inputs exposed to FX and logistics costs, with the industry warning in March that rising import costs were squeezing margins and production economics. Industry income fell about 20% in the first eight months of 2026 after repricing-driven growth of 25% and 40% in 2023 and 2024, Ouf told us earlier this month.

BACKGROUND- The country’s public health system is the single largest pharma buyer, purchasing through the Unified Procurement Authority — a centralized bulk-buying model designed to drive down costs. The same model created a payment bottleneck. When the government was cash-strapped, payments to manufacturers lagged. The government began clearing the runway earlier this year, settling 90% of its arrears to pharma companies.